Skip to main content
Premium Trial:

Request an Annual Quote

Quanterix Raises $2.5M, Targeting $5M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Diagnostics firm Quanterix has raised $2.5 million in a financing round targeting $5 million, it disclosed in a document filed with the US Securities and Exchange Commission this week.

The Cambridge, Mass., firm did not say how the funds will be used in its filing, but said it is not in connection with a business combination such as a merger, acquisition, or exchange offer.

The offering is in the form of options, warrants, or rights to acquire another security, and is not expected to last more than one year, it added. The date of the first sale from its offering was Sept. 28. Quanterix said nine investors have invested in the offering as of Oct. 11.

Founded in 2007, Quanterix is a development stage firm. Its lead technology is called Single Molecule Array, which it is using to develop and commercialize blood tests that measure protein levels in blood. The technology has sensitivity that is at least 1,000 times greater than standard laboratory tests, the company said on its website.